Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Semaglutide and beta-cell function in T1D
A 2026 case study reports preserved beta-cell function and stable blood sugar in a newly diagnosed type 1 diabetes patient treated with semaglutide.
Semaglutide cut fentanyl seeking in rats
A 2026 rat study found that single doses of semaglutide prevented cue-, drug- and stress-triggered fentanyl seeking. Human trials are next.
Semaglutide in HFpEF: German cost analysis
A German study finds semaglutide cost-effective for heart failure with preserved ejection fraction and obesity, with a five-year ICER of 30,443 EUR/QALY.
Ketone esters spare muscle on semaglutide
A JCI Insight mouse study finds ketone ester co-treatment preserves skeletal muscle mass during semaglutide therapy without reducing fat loss.
Semaglutide and Alzheimer's: EVOKE review
A new paper revisits the EVOKE trials and finds limited semaglutide signals at later timepoints, despite the primary endpoint failure at two years.
Semaglutide weight loss: the trial data
STEP 5 shows 15% average weight loss sustained at two years. What the data says about body composition, eating behaviour, and stopping.
Semaglutide resolves MASLD inflammation
A 2026 meta-analysis of 10 trials found semaglutide resolved steatohepatitis and cut liver fat in MASLD patients, but fibrosis improvement was not significant.
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
Semaglutide eased RLS in Parkinson's case
A 2026 case report found that semaglutide improved treatment-resistant restless legs syndrome in one Parkinson's disease patient. The finding is preliminary.
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
Who loses less weight on semaglutide?
A 163-patient retrospective study links diabetes, age over 60, and Hispanic ethnicity to lower weight loss on semaglutide at 12 months.
Most statin label warnings lack evidence
A 2026 Lancet meta-analysis found only 4 of 66 listed statin side effects are backed by trial evidence. What GLP-1 users should know.